ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SYRS Syros Pharmaceuticals Inc

5.80
0.00 (0.00%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Syros Pharmaceuticals Inc NASDAQ:SYRS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.80 5.76 26.00 6.1199 5.76 5.82 141,869 05:00:01

Syros to Participate in Upcoming Investor Conferences

21/11/2023 12:30pm

Business Wire


Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Syros Pharmaceuticals Charts.

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Management will also be available for one-on-one meetings. Details are as follows:

Piper Sandler 35th Annual Healthcare Conference Date: Tuesday, November 28 Presentation Time: 2:00 p.m. ET Location: The Lotte New York Palace, 455 Madison Ave, New York, NY

JMP Securities Hematology and Oncology Summit Date: Wednesday, December 6 Presentation Time: 11:00 a.m. ET Location: Virtual

To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARĪ± agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

Syros Contact Karen Hunady Director of Corporate Communications & Investor Relations 1-857-327-7321 khunady@syros.com

Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com

1 Year Syros Pharmaceuticals Chart

1 Year Syros Pharmaceuticals Chart

1 Month Syros Pharmaceuticals Chart

1 Month Syros Pharmaceuticals Chart